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Introduction
Pain is numerically the greatest clinical challenge of the age, 
affecting about half the population, whilst 7% of people have 
debilitating pain conditions1. Finding new analgesic targets 
and drugs has proved challenging. One approach has been to 
identify the genes involved in human monogenic loss of pain 
conditions2. The association of human gain-of-function muta-
tions in Nav1.7 with enhanced pain phenotypes, and the pain-free 
state linked to loss of Nav1.7 expression focused consider-
able attention on this voltage-gated sodium channel as a poten-
tial analgesic drug target3. Nav1.7 is found in damage-sensing 
peripheral sensory neurons, sympathetic neurons and CNS 
structures like the hypothalamus, as well as in non-neuronal 
locations such as the pancreas. Deletion in all sensory neurons 
and sympathetic neurons abolishes acute, inflammatory and 
neuropathic pain, although some pain disorders such as 
oxaliplatin-evoked cold allodynia are retained4,5.
As human and mouse Nav1.7-null mutants are effectively 
pain-free, this channel should be an excellent analgesic drug 
target6. However, channel blockers are very weak analgesics3,7. 
This is likely due to the fact that partial channel blocking 
cannot recapitulate the many physiological effects of gene 
deletion. This explanation is supported by experiments that 
show that only 100% channel block with very high dose 
tetrodotoxin can recapitulate some effects of gene deletion8. In 
null mutants, neurotransmitter release is diminished, and syn-
aptic integration is also diminished. In addition, the opioid 
peptide enkephalins are upregulated in the absence of Nav1.7, 
and opioid receptor signalling is potentiated. Both of these latter 
events may be linked to loss of sodium ingress through Nav1.78.
Consistent with an opioid component of analgesia, the opioid 
antagonist naloxone substantially reverses Nav1.7 loss-associated 
pain free phenotype8. We wondered which opioid receptors 
were involved in this process. Here, using pharmacological 
studies and opioid receptor knockout mice, we show that both 
µ-opioid receptors (MORs) and δ-opioid receptors (DORs) con-
tribute to Nav1.7-null mutant analgesia and deleting both recep-
tors mimics the effects of naloxone on Nav1.7-null analgesia 
in mice. In addition, we show that elevating enkephalin mRNA 
levels in NFAT5 null mutant mice similar to those found in 
Nav1.7 nulls is not alone sufficient to cause measurable analgesia.
Methods
Animals
Nav1.7 floxed mice were generated as described9. Specific dele-
tion of Scn9a exons 14 and 15 was performed by crossing 
Nav1.7flox/flox mice with Wnt1-Cretg/0 hemizygous transgenic mice 
purchased from Jackson Labs (129S4.Cg-Tg(Wnt1-cre)2Sor/J, 
Stock No: 022137). F1 offspring were crossed to obtain 
Nav1.7flox/flox:Wnt1-Cretg/0 and further bred with either MOR-/- or 
DOR-/- mice. Previously reported MOR- and DOR-null mutants 
were used10,11. We obtained Nav1.7flox/flox:MOR-/-:Wnt1-Cretg/0 and 
Nav1.7flox/flox:DOR-/-:Wnt1-Cretg/0. Finally, triple mutants carrying 
either MOR or DOR homozygous deletions were crossed in 
order to generate Nav1.7flox/flox:MOR-/-:DOR-/-:Wnt1-Cretg/0. For all 
mouse lines, homozygous mutants were compared to Wnt1-Cre-
negative animals. For clarity, Nav1.7flox/flox:DOR+/+:Wnt1-Cre0/0 are 
named in this article Nav1.7 WT / DOR WT; Nav1.7flox/flox:
DOR+/+:Wnt1-Cretg/0, Nav1.7 KO / DOR WT; Nav1.7flox/flox:DOR-/-: 
Wnt1-Cre0/0, Nav1.7 wt / DOR KO; and finally Nav1.7flox/flox:
DOR-/-:Wnt1-Cretg/0, Nav1.7 KO / DOR KO. The same simplifi-
cation was applied for all the genotypes. Nfat5 floxed mice were 
generated by Dr Cristina López-Rodriguez (Barcelona, Spain)12.
Experiments were conducted using both male and female 
mice, which were between 8 and 12 weeks old at the time of 
experiments. Animals were housed up to five per cage, in a 
temperature-controlled room with a 12-h light–dark cycle. Food 
and water were available ad libitum. Genotyping was carried 
out on genomic DNA extracted from ear notches and PCR was 
conducted as described9–11. Mice were euthanized by grad-
ual-fill CO2 gas followed by cervical dislocation at the end of 
experiments. A tail sample was further collected to confirm the 
genotype. Sample size for each experiment was established 
according to the literature. A total of 143 animals were used for 
the present work.
Behavioural testing
Animal experiments were approved by the UK Home Office 
and UCL ethics committee Act 1986 with prior approval under 
a Home Office project licence (PPL 70/7382). Mice were accli-
matized to the experimental room and were handled during a 
period of 1 week before starting the experiments. Observers 
who performed behavioural experiments were blinded to the 
genotype. All behaviour experiments were conducted between 
14h and 18h. For the Hargreaves thermal test, the animal’s 
hindpaw was exposed to an intense light beam and the with-
drawal latency recorded manually using the Hargreaves’ apparatus 
(Ugo Basile)13. For the Randall Selitto test, a blunt probe was 
used to apply force approximately midway along the tail (Ugo 
Basile)14. For the hot plate test, animals were exposed to a 55°C 
chamber floor and the withdrawal latency recorded15.
Drugs
In vivo experiments. Naloxone, Naltrindole hydrochloride 
(NTI), CTOP and nor-Binaltorphimine dihydrochloride (norBNI) 
were purchased from Sigma, UK and dissolved in saline; they 
were respectively administered 30 min, 30 min, 15 min and 
60 min, before performing behavioural experiments. Unless 
specified, all drugs were injected intraperitoneally at the dose 
described in the figure legend (typically, 2 mg/kg for naloxone, 
5 mg/kg for NTI, 1.5 mg/kg for CTOP and 10 mg/kg for norBNI).
In vitro experiments. Monensin, TTX and Veratridine (Sigma, 
UK) were respectively dissolved in ethanol, saline and DMSO. 
Ionomycin (Molecular Probes) was resuspended in DMSO. 
Monensin at 500 nM was incubated with DRG neurons for 
30 or 60 min. TTX at 500 nM and Veratridine at 1 µM were 
incubated 6h before harvesting the cells. For controls, the same 
volumes of vehicle were used. Same concentration of Mon-
ensin, TXT and Veratridine were applied in live cell imaging 
experiments, ionomycin was used at 200 nM.
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DRG neuron cultures
DRG from all spinal levels were harvested and dissociated as 
described16. Dissociated neurons were plated on poly-L-lysine- 
and laminin-coated 35-mm plastic dishes (Nunc, Denmark). 
Incubation with drugs was started at least 24 h after dissociation. 
Monensin (Sigma, UK, in 100% ethanol), TTX (Sigma, UK, in 
extracellular solution) or Veratridine (Sigma, UK, DMSO) were 
used at concentrations described in the figure legends before 
RNA extraction and quantification. For each experiment, control 
DRG neurons were treated with the appropriate vehicle.
Quantitative PCR
For fresh DRG analysis, DRG from lumbar segments L4, L5 
and L6 were harvested and pooled. For DRG cultures, cells were 
collected after incubation with the drug and concentrated by 
centrifugation. RNA was extracted using TRIzol® Reagent 
(Invitrogen) according to the manufacturer’s instructions. 
Reverse transcription was performed using iScript™ Reverse 
Transcription Supermix (Bio-Rad) for RT-qPCR following the 
Bio-Rad supplied protocol. cDNA amplification was performed 
in triplicate, using SsoAdvanced™ Universal SYBR® Green 
Supermix (Bio-Rad) with the following primers; Penk: forward 
5’ TTCAGCAGATCGGAGGAGT 3’, reverse 5’ AGAAGCGAACG-
GAGGAGAC 3’; Nav1.7 ex 7 forward 5’ TTTCCGGAAG-
GACCTTGAGC 3’, reverse CTGCCCTGAATCTGTGCTGA; 
Nav1.7 ex 14 forward 5’ GAGCACCATCCAATGACGGA 3’, 
reverse 5’ TTCAGCTGCGAAGATCCCTG 3’; Nfat5 ex 3-4 
forward 5’ AGTCAGACAAGCGGTGGTGA 3’, reverse 5’ 
CAGACACTCCCTGCTTCAGAG 3’; Nfat5 ex 6-7 forward 5’ 
TTGCAGACACCTTCTTCCCC 3’, reverse 5’ CTCTCCTT-
TCACTGAACAGCTA 3’; Gapdh forward 5’ TGCGACT-
TCAACAGCAACTC 3’, reverse 5’ CTTGCTCAGTGTCCTT-
GCTG 3’. Amplification were conducted with the following 
program: 3 min at 95°C, 40 cycles of 60°C for 10 sec, 72°C for 
10 sec, 95°C for 10 sec, and finally a melting curve for 10 min 
from 66°C to 100°C.
DNA amplification was quantified with a Bio-Rad CFX 
Connect™ Real-Time PCR Detection System thermocycler. 
The expression level of target genes was normalized to house-
keeping gene mRNA (Gapdh). Fold changes were determined 
using the 2−ΔΔCt equation17, in which wild-type littermate or 
vehicle-treated cultured DRG cDNA samples were designated 
as the calibrator. The data presented are given as the mean of the 
fold changes.
Live cell imaging
For Na+ imaging, neurons were loaded for 30 min with 5 µM of 
SBFI in serum free DMEM, and then washed with extracellular 
solution (140 mM NaCl, 3 mM KCl, 10 mM HEPES, 10 mM 
D-Glucose, 2 mM CaCl2, 1 mM MgCl2, pH 7.4 adjusted with KOH, 
Osmolarity 300 mOsm adjusted with D-Glucose). Cells were 
alternately excited at 340 and 380 nm and emissions at 510 nm 
collected separately to determine 340/380 nm ratio. Calibration 
of [Na+]i was performed by exposing SBFI-loaded DRG neurons 
to different extracellular solutions with specific Na+ concentra-
tion for 30 min (in the additional presence of 3 µM gramicidin 
D for equilibrium between intracellular and extracellular Na+ 
concentration). For Ca2+ imaging, cells were loaded with 1 µM of 
Fura-2 for 30 min and alternatively excited at 340 and 380 nm. 
Results were expressed using the ratio of the 340 nm/380 nm 
wavelengths.
Statistical analysis
Data were analysed using GraphPad Prism 7 (GraphPad 
Software Inc., San Diego, CA) and presented as mean ± SEM. 
Statistically significant differences between two groups were 
assessed by two-tailed unpaired t-test. p<0.05 was considered 
significant. Statistically significant differences between more 
than two groups were assessed by one-way ANOVA or two-way 
ANOVA for respectively non-repeated and repeated measures, 
followed by the post hoc test indicated in the figure legend. 
p<0.05 was considered significant. Statistical tests performed 
for a given experiment are described in figure legends.
An earlier version of this article can be found on bioRxiv (DOI: 
https://doi.org/10.1101/297184).
Results
Effects of MOR deletion on pain perception
We first examined the role of MORs in Nav1.7-null- 
associated analgesia (Figure 1A, B). Nav1.7-null mutant mice 
show dramatic thermal analgesia. Global deletion of MOR on a 
Nav1.7-null background had a small effect on acute heat pain 
behaviour (Figure 1A). This effect did not match the effects of 
naloxone, which substantially diminished analgesia (Figure 1B). 
Consistent with this, naloxone further diminished the analgesic 
phenotype of Nav1.7/MOR double-mutant mice, demonstrat-
ing that MORs alone do not account for the opioid-mediated 
component of Nav1.7-null-associated analgesia (Figure 1B).
Effects of DOR deletion on pain perception
Next, we tested the effect of deleting DOR on Nav1.7-null 
pain behaviour10. Once again, there was a small diminution in 
analgesia compared to Nav1.7-null mice (Figure 1C). Naloxone 
further diminished the analgesic phenotype of the Nav1.7/DOR 
double-null mutants (Figure 1D), demonstrating that DORs 
alone do not account for the opioid-mediated component of 
Nav1.7-null-associated analgesia. However, when the potent 
selective MOR antagonist CTOP was applied to DOR 
receptor-null mice18, the analgesia associated with Nav1.7 
deletion was reduced by the same level as with naloxone 
(Figure 1F). CTOP and the κ-opioid receptor (KOR) antagonist 
norbinaltorphimine (norBNI)19 together also had the same effect 
as naloxone when applied to a Nav1.7/DOR double-null animal 
(Figure 1E). However, norBNI on a Nav1.7/DOR null back-
ground was without effect (Figure 1G). These data show that 
KORs do not mediate analgesia in Nav1.7-null mutants, but 
pharmacological block of MOR on a DOR-null background can 
account for all opioid-mediated analgesia.
Effects of double MOR/DOR deletion on pain perception
To provide further evidence that both MOR and DOR contribute 
to opioid-mediated analgesia in Nav1.7 nulls, we generated 
double opioid receptor null mutant mice on a Nav1.7 null 
background. Double MOR/DOR knockouts on a Nav1.7-null 
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Figure 1. µ-opioid receptor (MOR) or δ-opioid receptor (DOR) deletion is not sufficient to reduce Nav1.7 knockout (KO) pain 
sensitivity. (A) Noxious thermal stimulation of Nav1.7 WT/MOR WT (white), Nav1.7 KO/MOR WT (red), Nav1.7 WT/MOR KO (blue) and 
Nav1.7 KO/MOR KO (purple) mouse hindpaw using Hargreave’s apparatus (n=5–9 per group). (B) Hindpaw withdrawal latency 20 
min after naloxone administration (2 mg/kg, i.p). The grey bars represent noxious thermal withdrawal latency baselines merged with 
latency measured 20 min after naloxone to facilitate comparison between pre and post drug injection pain-related behaviour. The same 
representation of baselines by grey bars has been applied for all behavioural experiments. Results are presented as means ± SEM. 
Data were analysed by one-way ANOVA followed by Dunnett’s post hoc test (A) or two-way ANOVA followed by Bonferroni post hoc test 
(B). * p<0.05 ** p<0.01 vs Nav1.7 WT/MOR WT; # p<0.05 vs own baseline). (C) Noxious thermal stimulation of Nav1.7 WT/DOR WT (white), 
Nav1.7 KO/DOR WT (red), Nav1.7 WT/DOR KO (yellow) and Nav1.7 KO/DOR KO (orange) mice (n=8 per group). (D) Hindpaw withdrawal 
latency 20 min after naloxone administration (2 mg/kg, i.p.). (E) Thermal withdrawal latency after a combination of the MOR antagonist CTOP 
(1.5 mg/kg, i.p.) and the kappa antagonist norbinaltorphimine (norBNI) (10 mg/kg, i.p.,) injected respectively 15 and 60 min before the test. 
(F) Effect of CTOP and (G) norBNI on mouse hindpaw withdrawal latency using Hargreave’s test (administrated 15 min or 60 min before 
recording the latency). Results are presented as mean ± SEM. Data were analysed by one-way ANOVA followed by Dunnett’s post hoc test 
(C) or two-way ANOVA followed by the Bonferroni post hoc test (D–G). * p<0.05 ** p<0.01 and *** p<0.001 vs Nav1.7 WT / DOR WT, # p<0.05 
## p<0.01 and ### p<0.001 vs own baseline.
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background showed exactly the same loss of analgesia as that 
caused by naloxone in Nav1.7 knockout mice (Figure 2A, B). 
Application of MOR, DOR and KOR antagonists20 together 
did the same (Figure 2D), although the KOR antagonist norBNI 
alone showed no statistically significant effect, confirming that 
KOR activation did not contribute to analgesia (Figure 2C). 
These pharmacological and genetic studies demonstrate that 
MOR and DOR together account for opioid-mediated analgesia in 
Nav1.7-null mutant mice.
Assessing the effect of sodium levels on Nav1.7 and Nfat5 
transcription
Elevated levels of enkephalins are found in Nav1.7-null mutant 
mice8. Notably, there are five consensus binding sites for the 
transcription factor Nfat5 upstream of the Penk coding region. 
Nfat5 recognizes DNA elements similar to those bound by 
Nfatc proteins21. As Nfat5 activity is regulated by hyper- 
osmolarity and salt kinases22, there is a potential link between 
sodium ingress through Nav1.7 and transcriptional regulation. 
Figure 2. Deletion of both MOR and DOR mimics Naloxone effects on Nav1.7 knockout (KO) pain thresholds. (A) Noxious thermal 
stimulation of Nav1.7 wild type (WT)/DOR x MOR WT (white), Nav1.7 KO/DOR x MOR WT (red), Nav1.7 WT/DOR x MOR KO (green) and 
Nav1.7 KO/DOR x MOR KO (black) mice hindpaw using Hargreave’s apparatus (n=7–8 per group). (B) Hindpaw withdrawal latency 20 
min after naloxone administration (2 mg/kg, i.p., saline). The grey bars represent noxious thermal withdrawal latency baselines merged 
with latency measured 20 min after naloxone to facilitate comparison between pre and post drug injection pain-related behaviour. 
(C) Thermal withdrawal latency after administration of norbinaltorphimine (norBNI) (10 mg/kg, i.p.) injected 60 min before the test. 
Results are presented as mean ± SEM. No statistically significant effect was seen. Data were analysed by one-way ANOVA followed 
by Dunnett’s post hoc test (A) or two-way ANOVA followed by the Bonferroni post hoc test (B and C). ** p<0.01 and *** p<0.001 vs 
Nav1.7 WT/DOR x MOR WT; # p<0.05 vs own baseline; ••• p<0.001 vs Nav1.7 WT/DOR x MOR KO. (D) Hindpaw withdrawal latency 
after administration of a combination of CTOP (2 mg/kg, i.p., saline, injected 15 min before the test), NTI (5 mg/kg, s.c., 30 min 
before test) and norBNI (10 mg/kg, i.p. 60 min before test) in WT (white bars) or Nav1.7 KO mice (red bars). Co-injection of MOR, 
DOR and κ-opioid receptor antagonists restores Nav1.7 KO thermal sensitivity. Results are presented as mean ± SEM. Data were analysed 
by two-way ANOVA followed by the Bonferroni post hoc test. *** p<0.001 vs Nav1.7 WT; ### p<0.001 vs baseline.
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We manipulated sodium levels in sensory neuron cultures using 
either monensin as a sodium ionophore (control [Na+] 6.65 mM, 
SEM 0.27; [Na+] monensin 9.46 mM, SEM 0.44; n = 19;) or 
veratridine as an activator of voltage-gated sodium channels 
(control [Na+] 5.5 mM, SEM 0.25; [Na+] veratridine 7.6 mM, 
SEM 0.41; n = 9) to increase sodium levels, and very high 
doses of tetrodotoxin (TTX) (500 nM) to block voltage-gated 
sodium channel activity and potentially lower intracellular 
sodium (Supplementary File 1). Notably, agents that alter intra-
cellular sodium concentrations impact similarly on Nav1.7 and 
Nfat5 mRNA levels. Monensin (Figure 3A) lowered both Penk 
and Nfat5 mRNA levels, whilst TTX elevated them (Figure 3B). 
Figure 3. Both Penk and Nfat5 expression are regulated by intracellular sodium concentration. (A) Penk and Nfat5 expression levels in 
cultured DRG neurons treated with monensin (500 nM, 30 and 60 min, respectively, light and dark blue bars). Control neurons (white bar) were 
treated with vehicle (ethanol) for 60 min. (B) Penk and Nfat5 mRNA quantification in cultured DRG neurons treated with tetrodotoxin (TTX) (500 
nM, 6 h). Control neurons received same volume of saline solution for 6 h (red bar). (C) Penk and (D) Nfat5 transcripts levels in wild-type (WT) 
compared to Nav1.7 knockout (KO) DRG neurons treated by TTX (500 nM, 6h). TTX induced Penk overexpression is correlated with Nfat5 
expression level, both are dependant of Nav1.7. (E) Penk and (F) Nfat5 expression in WT and Nav1.7 KO cultured DRG neurons treated with 
veratridine (1 µM, 6h). Results are presented as mean ± SEM. Data were analysed by two-way ANOVA followed by the Bonferroni post hoc 
test. * p<0.05 ** p<0.01 and *** p<0.001 vs Nav1.7 WT Vehicle.
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The TTX effect was apparent in wild-type mice, but not in 
Nav1.7 nulls, implying that this channel is the locus of action for 
Penk mRNA control by TTX (Figure 3C, D).
Effect of Nav1.7/Nfat5 knockout on pain reception
Veratridine lowered both Penk and Nfat5 mRNA levels in 
wild-type, but not in Nav1.7-null mutant mice, again linking 
transcriptional events to Nav1.7 channel activity (Figure 3E, F). 
We examined the role of Nfat5 using conditional Nfat5-Wnt1-Cre 
null mutants in sensory neurons of wild-type and Nav1.7-null 
mutant mice. Expression levels of Nfat5 and Nav1.7 transcripts 
in single- and double-mutants were analysed to confirm Cre 
activity at the floxed loci (Supplementary File 2). Nfat5 condi-
tional null mutant mice showed enhanced expression of Penk 
mRNA (Figure 4A). When the Nfat5-null mice were crossed 
with Nav1.7-null mutants, Penk mRNA levels further increased 
(Figure 4A). As Nfat5-null mice have the same levels of Penk 
mRNA as Nav1.7-null mutants, this allowed us to examine 
the contribution of enhanced opioid peptide expression to the 
analgesia seen in Nav1.7-null mutant mice. Opioid signalling 
in Nav1.7-null mutants is potentiated in at last two ways. First, 
there are enhanced levels of enkephalins, and second the opioid 
Figure 4. Nfat5 conditional gene deletion induces Penk overexpression in vivo without eliciting a pain-insensitive phenotype. 
(A) Expression levels of Penk transcript in Nav1.7 WT/NFAT5 wild type (WT) (white bar), Nav1.7 knockout (KO)/NFAT5 WT (red bar), Nav1.7 
WT/NFAT5 KO (light grey) and Nav1.7 KO/NFAT5 KO mice (dark grey). (B) Noxious mechanical pressure threshold of the same four mice 
lines using the Randall-Selitto apparatus. (C) Noxious thermal stimulation of Nav1.7 WT/NFAT5 WT (white bar), Nav1.7 KO/NFAT5 WT(red 
bar), Nav1.7 WT/NFAT5 KO (light grey) and Nav1.7 KO/NFAT5 KO mice (dark grey) mice hindpaw using Hargreave’s apparatus (n=7–10 per 
groups). (D) Response to noxious thermal stimulation by using the hotplate test at 55°C. Results are presented as mean ± SEM. Data were 
analysed by one-way ANOVA followed by the Dunnett’s post hoc test. * p<0.05 ** p<0.01 and *** p<0.001 vs Nav1.7 WT/NFAT5 WT. 
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receptors have much enhanced activity, as measured indirectly 
through the quantitation of protein kinase A signalling23. There 
was, perhaps surprisingly, no analgesic effect of elevated 
enkephalin levels in the Nfat5-null sensory ganglia. By measur-
ing noxious mechanosensation (Figure 4B), thermal thresholds 
(Figure 4C), and noxious heat-induced-pain-related behaviour 
(Figure 4D), the Nfat5-null enkephalin-induced mice showed 
normal pain behaviour, compared to Nav1.7-null mice (Figure 4). 
As opioids clearly play a role in Nav1.7-null analgesia, as 
demonstrated by the naloxone effects, this suggests that the 
enhanced activity of opioid receptors may make a major 
contribution to Nav1.7-null opioid-mediated analgesia.
All raw data are available on OSF24.
Discussion
What are the implications of these findings for drug develop-
ment? Firstly, the complexity of physiological changes that occur 
in Nav1.7-null mice is striking. Receptors (e.g. 5HTr4) and 
transcription factors (e.g. Runx1) implicated in nociception 
are dysregulated8, opioid peptide expression is increased8 and 
opioid signalling is potentiated23, whilst electrical excitability25 
and integration of nociceptive stimuli is lost26. There is evidence 
that these events require the complete loss of Nav1.7 function, as 
occurs in null mutants. For example, only complete channel 
blockade with very high doses of TTX can induce increased 
Penk mRNA expression8. Should small-molecule-specific 
Nav1.7 antagonists be able to replicate all these events then they 
would be excellent analgesics. All the evidence thus far 
demonstrates that this is not the case, and the necessarily partial 
blockade of Nav1.7 does not cause analgesia7. Molecules with 
limited specificity, like Biogen’s BIIB074, are good analgesics, 
but much of their activity likely results from blockade of sodium 
channels other than Nav1.722.
The role of MOR and DOR and the lack of a role for KOR in 
Nav1.7-null analgesia fit with recent data. There is evidence 
for MOR–DOR interactions in nociceptive sensory neurons27, 
and primates express MOR–DOR heteromultimers as targets of 
opioid analgesia28. As Nav1.7 deletion in peripheral nervous 
system-dependent Cre mice causes analgesia, then the actions on 
opioid receptors must occur either on primary sensory neurons, 
or on their synaptic targets within the spinal cord. Evidence that 
co-administration of opioids with Nav1.7 antagonists can have 
synergistic therapeutic effects has been demonstrated with a 
number of specific Nav1.7 antagonists. However, human 
proof-of-concept studies on synergistic analgesia with Nav1.7 
antagonists and opioids have yet to be published. The evidence 
for potentiation of opioid receptor signalling in Nav1.7-null mice 
is significant23. Although diminished electrical excitability may 
provide the necessary landscape for endogenous opioid effects, 
it is surprising that elevated enkephalin levels alone do not 
produce any detectable levels of analgesia in the Nfat5-null 
mice. Exogenous administration of enkephalins in humans 
delivered through gene therapy has useful analgesic effects29. 
The focus is then upon potentiated opioid receptor signalling23. 
There is some evidence linking the ingress of sodium through 
Nav1.7 to effects on G-protein-coupled receptor (GPCR) activity. 
Pert and Snyder showed the influence of sodium on opioid 
receptor activity in 1974, demonstrating that increased sodium 
concentrations caused diminished agonist binding30. Intracellular 
sodium levels may control this process31 and the proximity 
of Nav1.7 channels to opioid receptors may influence sodium 
occupancy of these GPCRs32.
In summary, MORs and DORs are required for the opioid 
component of Nav1.7-null mutant analgesia. Co administration 
of MOR/DOR agonists with specific Nav1.7 antagonists may 
therefore have useful analgesic effects33. If analgesia depends 
substantially upon both potentiated receptor activity, as well as 
increased enkephalin expression, analgesic drug development 
using small molecules to mimic Nav1.7 gene deletion will be 
problematic. Nociceptor silencing through CRISPR-mediated 
gene deletion of Nav1.7 may prove a more tractable analgesic 
strategy for extreme chronic pain conditions34.
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